

Notification of changes in shareholdings in Cereno Scientific AB

Cereno Scientific AB has been informed that Milad Pournouri has acquired an additional 40 000 shares in the company. Milad Pournouri's holdings amounted to 3 560 000 shares before the transaction, equivalent to 4.96% of the capital and 4.55% of the votes in the company. After the transaction the holdings amount to 3 600 000 shares, equivalent to 5.01% of the capital and 4.60% of the votes in the company.

For further information, please contact:

Daniel Brodén, CFO

Tel: +46 768 66 77 87

Email: info@cerenoscientific.com

www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeAcetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study for CS1 in PAH is expected to be initiated in mid-2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca's BioVenture Hub, Sweden, and has the US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.